The Effect of Cord Blood Serum Eyes Drops Administer in Patients With Severe Keratopathy Related to EGFR-I Treatment

Last updated: February 14, 2025
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Overall Status: Active - Recruiting

Phase

N/A

Condition

Dry Eyes

Dry Eye Disease

Sjogren's Syndrome

Treatment

administration cord blood based eye drops, standardized to the deliver BDNF.

Clinical Study ID

NCT06830551
OFTAFONTANA_DED_EGFR-I
F35F22000080001
  • Ages > 18
  • All Genders

Study Summary

The study aim to evaluate the efficacy of cord blood eye drops in the healing of the damaged corneal epithelium.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • age over 18 years

  • oncology and advanced cancer patients who have EGFr mutation and who requiretreatment with antiEGFr drugs

  • signing of informed consent

Exclusion

Exclusion Criteria:

  • Patients who are unable to store/administer the CSCO independently, or with the helpof care-givers.

Study Design

Total Participants: 10
Treatment Group(s): 1
Primary Treatment: administration cord blood based eye drops, standardized to the deliver BDNF.
Phase:
Study Start date:
September 12, 2023
Estimated Completion Date:
December 31, 2025

Study Description

Patients undergoing treatment with EGFR inhibitor for lung cancer might develop corneal damage.

The study aims to evaluate the healing of corneal epithelium by administering cord blood eye drops for one month.

Connect with a study center

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    Bologna, 40138
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.